Table of Contents
<< Previous Issue | Jun 2022 (Vol: 2022, Issue: 6) | Next Issue >> |
- Section: Licensing
-
Biogen Licenses Parkinson’s Drug from Alectos Therapeutics for up to US$722.5 M
-
MorphoSys Out-licenses Two Oncology Antibodies to HIBio
-
Immatics and Bristol Myers Squibb Expand Alliance to Develop Cell Therapy Programmes
- Section: Mergers & Acquisitions
-
GlaxoSmithKline Acquires Affinivax for US$3.3 B
-
Bristol Myers Squibb Buys Turning Point for US$4.1 B
- Section: Research & Development
-
Novartis Collaborates with Precision Bio in Gene Editing Pact